Scientific Reference

Peptide Encyclopedia

Comprehensive biochemical profiles — mechanisms, endogenous production, receptor pathways, and research data.

🔍

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

GLP-1 Agonist Metabolic Discovered: 2012 · Novo Nordisk

Emerging Research Landscape

Semaglutide is at the center of an expanding body of clinical research extending well beyond glycemic control. Key areas of active investigation include:

Weight Management & Obesity: Large-scale trials (STEP program) have demonstrated significant and sustained reductions in body weight, with ongoing studies evaluating long-term outcomes, weight maintenance after discontinuation, and effects in adolescent populations.

Cardiovascular Risk Reduction: The SELECT trial demonstrated reduced major adverse cardiovascular events (MACE) in overweight/obese adults without diabetes — the first GLP-1 RA to show CV benefit independent of glycemic control. Further trials are investigating heart failure outcomes and atherosclerotic plaque regression.

Metabolic-Associated Steatotic Liver Disease (MASLD): Clinical studies are evaluating semaglutide's impact on hepatic steatosis, liver fibrosis, and progression to steatohepatitis, with promising early results showing histological improvement in liver biopsies.

Chronic Kidney Disease: The FLOW trial investigated renal outcomes in patients with type 2 diabetes and CKD, examining whether GLP-1 receptor agonism confers direct nephroprotective effects beyond glycemic and weight-related benefits.

Neurodegenerative Disease: Preclinical and early clinical research is exploring GLP-1 receptor activation in the brain as a potential modifier of neuroinflammation, amyloid pathology, and cognitive decline in Alzheimer's disease and Parkinson's disease.

Addiction & Compulsive Behavior: Emerging observational data and preclinical models suggest GLP-1 receptor signaling in mesolimbic reward circuits may reduce alcohol consumption, nicotine dependence, and other compulsive behaviors — clinical trials are underway.

Obstructive Sleep Apnea: Studies are investigating whether the weight loss and potential direct airway effects of semaglutide reduce the severity of obstructive sleep apnea as measured by the apnea-hypopnea index.

Origin & Endogenous Context

Semaglutide is a synthetic analogue of Glucagon-Like Peptide-1 (GLP-1), a 30-amino-acid incretin hormone naturally produced by L-cells in the distal small intestine and colon in response to food ingestion. Endogenous GLP-1 has a plasma half-life of only 1–2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide was engineered by Novo Nordisk to share ~94% sequence homology with native GLP-1 while incorporating a C-18 fatty diacid chain at position 34 via a linker, enabling albumin binding and dramatically extending its half-life to approximately 165–184 hours.

Mechanisms of Action

GLP-1 Receptor Agonism: Binds the GLP-1 receptor (GLP1R), a class B G-protein-coupled receptor (GPCR), activating adenylyl cyclase via Gαs, increasing intracellular cAMP and downstream PKA/EPAC signaling.

Pancreatic β-Cell Stimulation: Augments glucose-dependent insulin secretion by enhancing Ca²⁺ influx through voltage-gated channels and inhibiting K⁺-ATP channels in β-cells.

Glucagon Suppression: Inhibits α-cell glucagon release, reducing hepatic glucose output in a glucose-dependent manner.

Gastric Emptying Delay: Slows gastric motility via vagal pathways, extending nutrient absorption duration and blunting postprandial glucose spikes.

Central Appetite Suppression: Acts on GLP1R in the hypothalamic arcuate nucleus (ARC) and nucleus tractus solitarius (NTS), reducing NPY/AgRP neuronal activity and increasing POMC/CART signaling to suppress appetite and increase satiety.

Cardiovascular Effects: Reduces major adverse cardiovascular events (MACE) via anti-inflammatory and direct myocardial GLP1R signaling pathways.

Primary Sources

Lau J, et al. (2015). Discovery of the Once-Weekly GLP-1 Analogue Semaglutide. J Med Chem, 58(18):7370–80.
Drucker DJ. (2018). The biology of incretin hormones. Cell Metab, 3(3):153–165.
Marso SP, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). NEJM, 375:1834–1844.

Tirzepatide

Also known as: Mounjaro, Zepbound

Dual GLP-1 / GIP Agonist Metabolic Developed: 2021 · Eli Lilly

Emerging Research Landscape

Tirzepatide's dual incretin mechanism has opened research avenues across multiple therapeutic domains:

Weight Management & Obesity: The SURMOUNT program demonstrated weight reductions of up to 22.5% in non-diabetic adults, with ongoing studies examining long-term durability, pediatric populations, and comparisons against other anti-obesity agents.

Type 2 Diabetes & Glycemic Control: SURPASS trials showed HbA1c reductions superior to insulin, semaglutide, and other comparators, with sustained beta-cell function improvement under investigation.

Cardiovascular Outcomes: Large-scale CV outcome trials are evaluating whether tirzepatide's dual agonism provides additive cardiovascular protection, including effects on heart failure with preserved ejection fraction (HFpEF).

Metabolic-Associated Steatotic Liver Disease (MASLD): The SYNERGY-NASH trial is assessing tirzepatide's effects on liver histology, with preclinical data suggesting GIP receptor co-activation may enhance hepatic lipid metabolism beyond GLP-1 alone.

Obstructive Sleep Apnea: Research is exploring whether tirzepatide-mediated weight loss and metabolic improvements reduce the severity of sleep-disordered breathing and associated cardiometabolic risk.

Polycystic Ovary Syndrome (PCOS): Early studies are investigating the impact on hormonal profiles, insulin resistance, and fertility outcomes in women with PCOS-related metabolic dysfunction.

Origin & Endogenous Context

Tirzepatide is a first-in-class dual incretin receptor agonist, designed to simultaneously activate both GLP-1 and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptors. GIP is a 42-amino-acid incretin secreted by K-cells in the duodenum and jejunum, historically considered a less potent target. Tirzepatide is a 39-residue synthetic peptide based on the GIP sequence with modifications enabling GLP-1R co-agonism, with a C20 fatty diacid moiety for albumin binding and a ~5-day half-life.

Mechanisms of Action

Dual Receptor Agonism: Balanced activation of both GIPR and GLP1R produces synergistic metabolic effects exceeding either pathway alone, as demonstrated in knockout mouse models.

Adipose Tissue Remodeling: GIPR activation on adipocytes promotes fatty acid uptake and storage regulation; combined GLP-1 signaling reduces visceral adiposity through independent mechanisms.

Enhanced Insulin Sensitization: GIP receptor signaling in muscle and adipose tissue augments insulin sensitivity beyond GLP-1 effects alone, with reduced compensatory insulin secretion requirements.

Central Feeding Circuits: Engages both GLP1R and GIPR in hypothalamic circuits controlling energy expenditure, reducing caloric intake via dual neurohormonal satiety signaling.

β-Cell Protection: Preclinical data suggests dual agonism supports pancreatic β-cell mass preservation and reduces glucotoxicity-induced apoptosis.

Primary Sources

Frías JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. NEJM, 385:503–515.
Coskun T, et al. (2022). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab, 18:3–14.
Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 387:205–216.

Retatrutide

Also known as: LY3437943 · Triple Agonist

GLP-1 / GIP / Glucagon Agonist Metabolic Investigational · Eli Lilly · Phase III

Emerging Research Landscape

As the first triple-agonist peptide in clinical development, retatrutide has generated significant interest across multiple research domains:

Severe Obesity & Unprecedented Weight Reduction: Phase 2 trials demonstrated weight loss of up to 24% at 48 weeks — among the highest recorded for any pharmacological intervention — with Phase 3 programs evaluating long-term safety and durability.

Type 2 Diabetes: Glycemic control studies are assessing whether triple receptor agonism provides superior HbA1c reduction and beta-cell preservation compared to dual and single agonists.

Metabolic-Associated Steatotic Liver Disease (MASLD): The glucagon receptor component is of particular interest for hepatic fat reduction, as glucagon agonism directly promotes hepatic lipid oxidation and reduces de novo lipogenesis — early data shows dramatic reductions in liver fat content.

Energy Expenditure & Thermogenesis: The GCG receptor arm is being studied for its potential to increase resting energy expenditure and activate brown adipose tissue, which could contribute to weight loss maintenance beyond appetite suppression alone.

Cardiovascular & Renal Outcomes: Researchers are evaluating whether the additive effects of three receptor pathways translate into improved cardiovascular and renal outcomes compared to existing mono- and dual-agonist therapies.

Origin & Endogenous Context

Retatrutide represents the next frontier in incretin-based therapy — a triple receptor agonist simultaneously engaging GLP-1R, GIPR, and the Glucagon Receptor (GCGR). Glucagon, a 29-amino-acid peptide secreted by pancreatic α-cells, is best known for raising blood glucose, but GCGR signaling in adipose tissue, liver, and brown adipose tissue (BAT) drives potent energy expenditure and lipolysis. Retatrutide's co-engagement of GCGR adds thermogenic energy expenditure on top of the appetite suppression of GLP-1 and metabolic sensitization of GIP.

Mechanisms of Action

Triple Incretin Agonism: Simultaneous activation of GLP1R, GIPR, and GCGR leverages three independent but complementary metabolic axes, producing additive reductions in body weight exceeding any dual combination.

Hepatic Fat Reduction: GCGR activation in the liver stimulates glycogenolysis and reduces hepatic lipid accumulation (NAFLD/NASH), while GLP-1 reduces de novo lipogenesis.

Brown Adipose Thermogenesis: GCGR signaling upregulates uncoupling protein-1 (UCP-1) in brown adipose tissue, increasing non-shivering thermogenesis and basal energy expenditure.

Lipolysis Acceleration: Glucagon receptor activation on white adipocytes increases intracellular cAMP, activating hormone-sensitive lipase (HSL) and accelerating triglyceride hydrolysis.

Primary Sources

Jastreboff AM, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM, 389:514–526.
Coskun T, et al. (2022). Retatrutide (LY3437943) is a novel triple GIP, GLP-1 and glucagon receptor agonist. Diabetes Obes Metab.

BPC-157

Body Protection Compound-157 · Pentadecapeptide

Repair & Recovery Isolated: 1991 · University of Zagreb

Emerging Research Landscape

BPC-157 has been the subject of extensive preclinical research, with investigators exploring its potential across a remarkably broad range of biological systems:

Musculoskeletal Tissue Repair: Preclinical models have investigated BPC-157's effects on tendon, ligament, muscle, and bone healing — including accelerated recovery of transected tendons, crushed muscles, and segmental bone defects — with proposed mechanisms involving upregulation of growth hormone receptors and FAK-paxillin pathway activation.

Gastrointestinal Protection & Healing: Research has examined its cytoprotective effects across multiple GI injury models including ulcers, inflammatory bowel disease (IBD), fistulas, esophageal lesions, and short bowel syndrome, with particular interest in its effects on gut mucosal integrity and intestinal anastomosis healing.

Angiogenesis & Wound Healing: Studies show BPC-157 promotes new blood vessel formation via VEGF upregulation and endothelial cell migration, with implications for chronic wound healing, skin burns, and surgical recovery.

Neuroprotection & Neural Repair: Investigators have studied its effects on peripheral nerve regeneration, traumatic brain injury, and spinal cord injury models, as well as potential modulation of the dopaminergic and serotonergic systems in the context of depression and anxiety.

Organ Protection: Research extends to models of liver, kidney, and cardiac injury — including NSAID-induced damage, alcohol toxicity, and ischemia-reperfusion injury — suggesting systemic cytoprotective properties via the nitric oxide (NO) system.

Joint Health: Preclinical data suggests potential effects on cartilage repair, osteoarthritis progression, and synovial inflammation, though human trials remain limited.

Origin & Endogenous Production

BPC-157 is a 15-amino-acid peptide fragment derived from the sequence of Body Protection Compound (BPC), a protein naturally present in human gastric juice at trace concentrations. It was first isolated and characterized by Dr. Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. Unlike many synthetic peptides, BPC-157 appears to represent a naturally occurring cytoprotective sequence that the gastric mucosa utilizes as part of its intrinsic repair and defense mechanisms. Its sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) has no known endocrine gland of origin but is constitutively present in stomach secretions.

Mechanisms of Action

Fibroblast Stimulation & Collagen Synthesis: Upregulates growth hormone receptor (GHR) expression on fibroblasts, accelerating fibroblast migration, proliferation, and collagen type I and III synthesis — the primary structural proteins of tendons, ligaments, and connective tissue.

Angiogenesis via VEGF Upregulation: Potently stimulates VEGF (Vascular Endothelial Growth Factor) expression through activation of the VEGFR2/FAK/Paxillin signaling cascade, promoting the formation of new blood vessels into ischemic or injured tissue.

Nitric Oxide System Modulation: Interacts bidirectionally with the nitric oxide (NO) system — upregulating eNOS in vascular endothelium to improve local perfusion, while simultaneously counteracting the cytotoxic effects of NO overproduction in inflammatory conditions.

Cytokine Modulation & Anti-inflammation: Reduces pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 at injury sites while preserving the early acute inflammatory phase necessary for tissue repair. Demonstrated to inhibit NF-κB pathway activation.

Gut-Brain Axis Signaling: Activates vagal nerve afferents and modulates dopamine and serotonin systems in the enteric and central nervous system, contributing to gastroprotective and potential neuroprotective effects.

Tendon-to-Bone Healing: Demonstrated to accelerate enthesis (tendon-to-bone insertion) healing in animal models by promoting cellular ingrowth, collagen fibril alignment, and bone morphogenetic protein (BMP) expression at the healing interface.

Primary Sources

Sikiric P, et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol, 16(10):1523–1535.
Chang CH, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol, 110(3):774–780.
Tkalcevic VI, et al. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds. Eur J Pharmacol, 570(1-3):212–221.

TB-500 (Thymosin Beta-4)

Tβ4 · Synthetic fragment of endogenous Thymosin Beta-4

Repair & Recovery Immune Thymosin Beta-4 isolated: 1966 · NCI

Emerging Research Landscape

TB-500 and its parent molecule Thymosin Beta-4 have attracted research interest across diverse tissue repair and regenerative medicine applications:

Cardiac Repair & Regeneration: Research has investigated Tβ4's ability to activate cardiac progenitor cells, reduce scar formation after myocardial infarction, and promote neovascularization in ischemic myocardium — with studies showing improved ejection fraction and reduced infarct size in animal models.

Wound Healing & Dermal Repair: Studies have examined accelerated wound closure, enhanced keratinocyte migration, and reduced scarring through G-actin sequestration and laminin-332 upregulation, with implications for chronic wounds, surgical healing, and corneal repair.

Musculoskeletal Recovery: Preclinical research is exploring effects on muscle fiber regeneration, tendon repair, and reduction of inflammation-driven tissue damage following exercise-induced or traumatic injury.

Neurological Repair: Animal models have investigated Tβ4 in traumatic brain injury and stroke, focusing on oligodendrocyte differentiation, remyelination, and functional neurological recovery.

Anti-Fibrotic Properties: Research is examining Tβ4's potential to reduce pathological fibrosis in liver, kidney, and lung tissue, with proposed mechanisms involving inhibition of TGF-β signaling and myofibroblast differentiation.

Ophthalmic Applications: RegeneRx Biopharmaceuticals has studied Tβ4 (RGN-259) for corneal wound healing, neurotrophic keratitis, and dry eye disease, with clinical trials demonstrating improved corneal healing rates.

Origin & Endogenous Production

Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino-acid peptide found in virtually every nucleated cell of the human body, with particularly high concentrations in platelets, white blood cells, and wound fluids. It was first isolated from thymic tissue by Low and colleagues in 1981 after the broader thymosin fraction was identified in the 1960s. Tβ4 is among the most abundant intracellular peptides in mammals, estimated at 0.5% of total cellular protein in some tissues. It is constitutively expressed but significantly upregulated following injury. TB-500 refers to a synthetic version of the active fragment of Tβ4, specifically the actin-binding domain (amino acids 17–23: LKKTETQ).

Mechanisms of Action

G-Actin Sequestration: Tβ4's primary biochemical function is binding monomeric G-actin with high affinity (Kd ~0.7 µM), maintaining a soluble pool of actin monomers available for rapid cytoskeletal remodeling — essential for cell migration during wound healing.

Stem Cell Activation & Migration: Promotes the migration and differentiation of progenitor cells, including cardiac progenitor cells (Isl-1+ cells) and satellite cells in skeletal muscle, accelerating endogenous tissue regeneration.

Anti-Inflammatory Gene Regulation: Downregulates inflammatory cytokines including NF-κB-dependent genes via interaction with the IKK complex, simultaneously upregulating anti-apoptotic proteins including Bcl-2.

Angiogenesis: Stimulates endothelial cell migration and tube formation via upregulation of laminin-5, integrin-linked kinase (ILK), and VEGF secretion.

Cardiac Regeneration: In landmark studies by Limana et al., Tβ4 was shown to activate epicardial progenitor cells in the heart, inducing cardiomyocyte differentiation and neovascularization in infarcted myocardium.

Primary Sources

Goldstein AL, et al. (2012). Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther, 12(Suppl 1):S37–51.
Smart N, et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 445(7124):177–182.
Huff T, et al. (2001). Beta-thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol, 33(3):205–220.

GHK-Cu

Glycyl-L-histidyl-L-lysine · Copper Peptide

Tissue Repair Longevity Discovered: 1973 · Loren Pickart, UCSF

Emerging Research Landscape

GHK-Cu has generated significant research interest due to its broad gene-modulatory effects, with investigators exploring its potential across several domains:

Skin Aging & Rejuvenation: Studies have investigated GHK-Cu's ability to stimulate collagen I, III, and V synthesis, increase elastin production, upregulate glycosaminoglycans (including decorin and hyaluronic acid), and improve skin thickness, firmness, and elasticity — with clinical trials showing measurable improvements in photoaged skin.

Hair Growth & Follicle Health: Research has examined GHK-Cu's effects on hair follicle size, proliferation of follicular keratinocytes, and stimulation of the anagen (growth) phase — with proposed mechanisms involving Wnt/β-catenin pathway modulation and increased dermal papilla cell activity.

Wound Healing & Tissue Remodeling: Preclinical data demonstrates accelerated wound contraction, enhanced angiogenesis, and improved tensile strength of healed tissue, with research extending to chronic ulcer management and post-surgical recovery.

Gene Expression Reset: Broad-spectrum genomic studies by Pickart et al. identified that GHK-Cu modulates expression of over 4,000 human genes, resetting many toward a younger, healthier pattern — an area of active investigation in aging biology and longevity research.

Anti-Inflammatory & Antioxidant Effects: Research is examining GHK-Cu's ability to reduce oxidative damage, suppress pro-inflammatory cytokines (IL-6, TNF-α), and modulate NF-κB signaling, with implications for chronic inflammatory conditions and neurodegeneration.

Bone Density & Remodeling: Preclinical investigations suggest GHK-Cu promotes osteoblast differentiation, stimulates BMP-2 expression, and may support bone mineral density — a topic of growing interest in age-related osteoporosis research.

Origin & Endogenous Production

GHK-Cu (Glycyl-L-histidyl-L-lysine complexed with copper²⁺) is a naturally occurring tripeptide found in human plasma, saliva, and urine. It was first identified by Loren Pickart in 1973 when he observed that plasma from young subjects rejuvenated aged liver tissue function. Plasma concentrations of GHK are approximately 200 ng/mL in young adults, declining significantly with age to ~80 ng/mL by age 60 — a pattern consistent with its proposed role as an endogenous age-modulating signal. GHK is naturally released during tissue breakdown (proteolysis), suggesting it functions as a damage-sensing signal that recruits repair machinery.

Mechanisms of Action

Gene Expression Remodeling: Microarray studies by Pickart and Margolina demonstrate GHK-Cu modulates over 4,000 genes, upregulating collagen, elastin, and glycosaminoglycan synthesis while downregulating genes associated with inflammation and tumor progression (including TGF-β1 and TNF-α).

Copper Transport & Enzymatic Activation: The copper ion in GHK-Cu activates copper-dependent enzymes including lysyl oxidase (essential for collagen and elastin crosslinking), superoxide dismutase (SOD1/SOD3 — antioxidant defense), and ceruloplasmin.

Stem Cell Recruitment: Chemotactically attracts fibroblasts, mast cells, and macrophages to wound sites; stimulates fibroblast proliferation and growth factor production including FGF and VEGF.

Antioxidant Defense: Upregulates endogenous antioxidant enzymes; the copper complex itself can chelate free iron, reducing hydroxyl radical generation via Fenton chemistry.

DNA Repair Activation: Shown to activate DNA repair pathways, including upregulation of BRCA1/2 and ATM expression, and to reset gene expression patterns toward a more youthful phenotype in aging fibroblast cultures.

Primary Sources

Pickart L & Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci, 19(7):1987.
Pickart L. (1981). The human tripeptide GHK (Gly-His-Lys) and tissue remodeling. J Biomater Sci Polym Ed.
Gorouhi F & Maibach HI. (2009). Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci, 31(5):327–345.

Epitalon (Epithalon)

Tetrapeptide · Ala-Glu-Asp-Gly

Longevity Neuroendocrine Developed: 1980s · Prof. Vladimir Khavinson, USSR

Emerging Research Landscape

Epitalon occupies a unique position in biogerontology research, with investigations centered on its telomere-modulating and neuroendocrine properties:

Telomere Length & Cellular Longevity: Research by Khavinson and colleagues has investigated Epitalon's ability to activate telomerase in human somatic cells, with studies reporting elongation of telomeres in cultured fibroblasts and retinal pigment epithelial cells — an area of active interest in aging and cellular senescence research.

Circadian Rhythm & Sleep Regulation: Studies have examined Epitalon's effects on pineal melatonin secretion, with data suggesting restoration of nocturnal melatonin peaks in aged subjects — potentially relevant to age-related sleep disruption and circadian dysregulation.

Neuroendocrine Aging: Long-term animal studies from the Khavinson laboratory have investigated Epitalon's effects on the aging neuroendocrine axis, including pituitary function, gonadotropin regulation, and the hypothalamic-pituitary-adrenal (HPA) axis.

Antioxidant Defense: Research has explored Epitalon's potential to upregulate endogenous antioxidant enzyme activity (superoxide dismutase, glutathione peroxidase, catalase) and reduce lipid peroxidation, particularly in aged tissues.

Retinal Health: Preclinical studies have investigated Epitalon's neuroprotective effects on retinal pigment epithelium, with proposed applications in age-related macular degeneration and retinitis pigmentosa.

Lifespan Extension: Long-term rodent studies have reported increased mean and maximum lifespan following Epitalon administration, with proposed mechanisms involving reduced spontaneous tumor incidence and enhanced immune surveillance — though these findings await replication in larger, independent cohorts.

Origin & Endogenous Context

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide analogue of Epithalamin, a natural polypeptide extract derived from the pineal gland. It was developed and extensively studied by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Epithalamin (the endogenous precursor) is secreted by pinealocytes and plays a central role in circadian rhythm regulation, neuroendocrine signaling, and the aging process. Epitalon represents the minimal bioactive sequence responsible for Epithalamin's bioregulatory effects.

Mechanisms of Action

Telomerase Activation: Epitalon's most studied mechanism involves activation of telomerase (hTERT), the reverse transcriptase enzyme responsible for adding TTAGGG repeats to chromosome ends. Khavinson's studies demonstrated telomere lengthening in cultured somatic cells following Epitalon treatment — a finding with profound implications for cellular senescence.

Pineal Melatonin Regulation: Stimulates the pineal gland to normalize melatonin secretion, particularly in aged organisms where pineal calcification and reduced melatonin output are associated with circadian dysregulation and accelerated aging.

Antioxidant Enhancement: Increases activity of superoxide dismutase (SOD) and catalase, reducing oxidative stress markers including MDA (malondialdehyde) and 8-OHdG (oxidative DNA damage).

Hypothalamic-Pituitary Axis Normalization: Corrects age-related dysregulation of the hypothalamic-pituitary axis by modulating sensitivity of hypothalamic neurons to corticosteroid feedback.

Oncostatic Effects: Several studies in rodent models demonstrate reduced spontaneous tumor incidence and inhibition of tumor angiogenesis following long-term Epitalon administration.

Primary Sources

Khavinson V & Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett, 24(3-4):233–240.
Khavinson VK, et al. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med, 135(6):590–2.
Anisimov VN, et al. (2011). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 4(4):193–202.

CJC-1295

Modified GRF(1-29) · GHRH Analogue

GHRH Analogue Developed: 2005 · ConjuChem Inc.

Emerging Research Landscape

CJC-1295's ability to amplify endogenous growth hormone pulsatility has driven research interest across multiple physiological domains:

Body Composition & Fat Metabolism: Clinical studies have investigated CJC-1295's effects on visceral adiposity, lean body mass, and lipid metabolism — with sustained GH elevation promoting lipolysis and shifting fuel utilization toward fat oxidation.

Sleep Quality & Architecture: GH is predominantly secreted during slow-wave sleep, and researchers are examining whether augmenting GHRH signaling with CJC-1295 improves sleep depth, recovery, and overall sleep architecture — particularly in aging populations with declining nocturnal GH pulses.

Muscle Recovery & Athletic Performance: Research is evaluating the role of sustained, physiologic GH elevation in accelerating exercise recovery, reducing muscle damage markers, and supporting protein synthesis during resistance training.

Bone Mineral Density: GH and IGF-1 are critical regulators of bone remodeling, and studies are exploring whether CJC-1295-mediated GH elevation improves bone density and reduces fracture risk in age-related osteopenia.

Age-Related GH Decline (Somatopause): Investigators are studying CJC-1295 as a potential intervention for the progressive decline in GH output that begins in the third decade of life, with focus on whether restoring youthful GH pulsatility improves metabolic, cognitive, and physical markers of aging.

Skin & Connective Tissue: GH-mediated collagen synthesis and fibroblast proliferation are being examined for their role in skin thickness, wound healing, and connective tissue integrity.

Origin & Endogenous Context

CJC-1295 is a 29-amino-acid synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), the endogenous hypothalamic peptide responsible for stimulating pituitary GH secretion. Endogenous GHRH has a plasma half-life of only ~7 minutes due to DPP-4 cleavage. CJC-1295 incorporates four amino acid substitutions to resist proteolytic degradation and, in its DAC (Drug Affinity Complex) form, includes a maleimidoproprionic acid (MPA) moiety that enables covalent albumin binding, extending the half-life to 6–8 days while preserving GHRH receptor specificity.

Mechanisms of Action

GHRH Receptor (GHRHR) Activation: Binds pituitary GHRHR (a class B GPCR), activating Gαs → adenylyl cyclase → cAMP → PKA cascade, stimulating GH gene transcription and pulsatile GH secretion from somatotroph cells.

Amplification of Endogenous GH Pulsatility: Rather than creating supraphysiological flat GH levels, CJC-1295 amplifies the amplitude of existing GH pulses while preserving the natural episodic secretion pattern — reducing risks associated with continuous GH elevation.

IGF-1 Elevation: Downstream GH signaling in the liver and peripheral tissues stimulates IGF-1 synthesis via JAK2/STAT5b pathway, mediating the anabolic, lipolytic, and tissue-repair effects associated with the GH axis.

Somatostatin Independence: Unlike exogenous GH administration, GHRH-axis stimulation remains subject to normal somatostatin-mediated feedback, preserving the GH:IGF-1 axis auto-regulation.

Primary Sources

Jetté L, et al. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: A Comparison of the Pharmacological Properties of Several Albumin Conjugates. J Pharmacol Exp Ther, 317(3):1007–1013.
Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3):799–805.

Ipamorelin

NNC 26-0161 · Selective GHRP

Ghrelin Mimetic / GHRP Developed: 1998 · Novo Nordisk

Emerging Research Landscape

Ipamorelin's selective GH-releasing profile — without cortisol or prolactin elevation — has made it a focus of research in several areas:

Body Composition Optimization: Studies have investigated Ipamorelin's effects on reducing adiposity and increasing lean mass through selective GH release, with particular interest in its favorable side-effect profile compared to older GH secretagogues like GHRP-6.

Post-Surgical Recovery & GI Function: Clinical research (notably Phase II trials by Helsinn) has examined Ipamorelin's ability to accelerate postoperative bowel recovery, reduce ileus duration, and shorten hospital stays following abdominal surgery.

Sleep Quality & Recovery: Ghrelin receptor agonism at bedtime is being studied for its effects on slow-wave sleep enhancement, overnight GH secretion, and physical recovery — with Ipamorelin's selectivity reducing the sleep-disrupting cortisol spikes seen with less specific secretagogues.

Bone Health: Preclinical research has evaluated Ipamorelin's anabolic effects on bone formation markers, osteoblast activity, and bone mineral density, with proposed applications in osteoporosis and fracture healing.

Muscle Recovery & Exercise Performance: The GH pulse stimulated by Ipamorelin is being studied for its role in reducing exercise-induced muscle damage, accelerating recovery between training sessions, and supporting myofibrillar protein synthesis.

Anti-Aging & Skin Health: Researchers are exploring whether restoring youthful GH pulsatility with Ipamorelin improves skin elasticity, collagen density, and overall dermal quality in aging populations.

Origin & Endogenous Context

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) belonging to the Growth Hormone Releasing Peptide (GHRP) class. It mimics ghrelin, the 28-amino-acid "hunger hormone" produced by gastric X/A-like cells, which serves as the endogenous ligand for the Growth Hormone Secretagogue Receptor (GHSR-1a). Ipamorelin was specifically engineered for its high selectivity — it stimulates GH release without the ACTH/cortisol or prolactin spikes seen with earlier GHRPs like GHRP-6, making it the cleanest GH secretagogue in its class.

Mechanisms of Action

GHSR-1a Agonism: Binds the growth hormone secretagogue receptor-1a in pituitary somatotrophs and hypothalamic neurons, activating Gαq/11 → PLCβ → IP3/DAG → PKC cascade and Ca²⁺ mobilization, triggering GH vesicle exocytosis.

Somatostatin Suppression: Partially inhibits somatostatin (SRIH) release from hypothalamic neurons, disinhibiting pituitary GH secretion — a complementary mechanism to GHRH-pathway stimulation.

Synergy with GHRH: When co-administered with CJC-1295, Ipamorelin acts on an entirely different receptor (GHSR vs. GHRHR), producing synergistic GH release that far exceeds either peptide alone — a well-characterized clinical combination.

Cortisol / Prolactin Selectivity: Unlike GHRP-2 and GHRP-6, Ipamorelin shows no significant stimulation of ACTH, cortisol, or prolactin secretion at therapeutic doses, confirmed in multiple comparative pharmacological studies.

Primary Sources

Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 139(5):552–561.
Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci, 54(12):1316–29.

Sermorelin

GHRH(1-29) · GRF(1-29)-NH₂

GHRH Analogue Synthesized: 1970s · Roger Guillemin, Salk Institute

Emerging Research Landscape

As the most studied GHRH analogue with prior FDA approval, Sermorelin has an established research base with ongoing investigations across multiple domains:

Sleep Quality & Architecture: Research has demonstrated that GHRH administration increases slow-wave sleep duration and depth. Studies with Sermorelin are investigating improvements in sleep onset latency, deep sleep percentage, and overnight recovery — particularly relevant for age-related sleep deterioration.

Skin & Hair Health: GH-mediated increases in collagen synthesis, dermal fibroblast activity, and growth factor signaling are being studied for their effects on skin thickness, elasticity, hair follicle vitality, and overall dermal aging.

Body Composition & Muscle Growth: Clinical studies have evaluated Sermorelin's capacity to increase lean body mass, reduce visceral fat, and support muscle protein synthesis through restored physiologic GH pulsatility — without the supraphysiologic peaks associated with exogenous GH.

Bone Density & Skeletal Health: Research has investigated whether Sermorelin-induced GH/IGF-1 elevation improves bone mineral density and reduces fracture risk, with studies in postmenopausal women and elderly populations showing improved markers of bone formation.

Recovery & Tissue Repair: The role of endogenous GH in tissue repair is being explored through Sermorelin's effects on post-exercise recovery, surgical wound healing, and connective tissue remodeling.

Cognitive Function: GH and IGF-1 receptors are expressed throughout the hippocampus and cortex, and researchers are examining whether restoring GH pulsatility with Sermorelin improves memory consolidation, cognitive processing speed, and neuroprotective signaling in aging adults.

Origin & Endogenous Context

Sermorelin is a 29-amino-acid synthetic peptide corresponding to the first 29 residues of endogenous GHRH(1-44), the full-length hypothalamic growth hormone-releasing hormone. GHRH was isolated by Roger Guillemin in 1982 (Nobel Prize 1977 for related hypothalamic hormone work). Sermorelin retains full biological activity as the 1-29 fragment contains the complete receptor-binding domain of GHRH. It was FDA-approved as Geref for pediatric GH deficiency before being discontinued for commercial reasons unrelated to safety.

Mechanisms of Action

Pituitary GHRHR Activation: Binds and activates the pituitary GHRH receptor, stimulating Gαs/adenylyl cyclase/cAMP/PKA signaling, increasing GH mRNA transcription and pulsatile secretion from somatotroph cells.

Physiological GH Pulse Restoration: Because it works through the hypothalamic-pituitary axis, Sermorelin preserves natural feedback mechanisms — IGF-1 and GH feed back on the pituitary and hypothalamus to prevent excess GH secretion, making it self-regulating.

Pituitary Somatotroph Maintenance: Long-term GHRH signaling maintains somatotroph cell populations and GH secretory capacity, preventing the atrophy of GH-secreting cells that occurs with exogenous GH supplementation.

Primary Sources

Walker RF. (2006). Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging, 1(4):307–308.
Prakash A & Goa KL. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2):139–157.

Tesamorelin

TH9507 · Egrifta · GHRH(1-44) analogue

GHRH Analogue Lipid Metabolism FDA Approved: 2010 · Theratechnologies

Emerging Research Landscape

As the only FDA-approved GHRH analogue currently on the market, Tesamorelin has a robust clinical evidence base with expanding research frontiers:

Visceral Adiposity Reduction: FDA-approved for HIV-associated lipodystrophy, Tesamorelin has demonstrated significant reductions in trunk fat and visceral adipose tissue (VAT). Research is investigating its application in non-HIV visceral obesity and metabolic syndrome.

Hepatic Fat & Liver Health: Clinical trials (Stanley et al., Lancet HIV 2019) have shown Tesamorelin reduces hepatic fat fraction and may slow progression of liver fibrosis — an active area of research given the growing prevalence of metabolic-associated steatotic liver disease (MASLD).

Cognitive Function & Neuroprotection: Studies in HIV-positive adults have investigated Tesamorelin's effects on cognitive performance, with preliminary data suggesting improvements in executive function and verbal memory linked to restored GH/IGF-1 signaling in the brain.

Cardiovascular Risk Markers: Research has examined the effects of VAT reduction on cardiovascular biomarkers including CRP, triglycerides, and carotid intima-media thickness, investigating whether Tesamorelin's body composition changes translate to reduced cardiovascular risk.

Muscle Mass & Physical Performance: The sustained GH elevation from Tesamorelin is being studied for effects on lean body mass, exercise capacity, and physical function — particularly in populations with sarcopenic obesity or age-related muscle wasting.

Bone Metabolism: Investigators are evaluating whether Tesamorelin-induced IGF-1 elevation promotes bone formation and improves bone mineral density markers in populations at risk for osteoporosis.

Origin & Endogenous Context

Tesamorelin is a synthetic analogue of the full-length 44-amino-acid GHRH(1-44), with the addition of a trans-3-hexenoic acid group at the N-terminus, which confers resistance to DPP-4 cleavage and extends the half-life from minutes to ~38 minutes. It is the only FDA-approved GHRH analogue, indicated for reducing excess visceral adipose tissue (VAT) in HIV-infected adults with lipodystrophy. Its clinical approval provides the strongest regulatory validation of GHRH analogue safety and efficacy in adults.

Mechanisms of Action

Full-Length GHRHR Activation: As an analogue of complete GHRH(1-44), Tesamorelin engages the full receptor-binding interface with slightly higher potency than shorter analogues, producing more robust pituitary GH secretion per molar dose.

Visceral Adipose Tissue (VAT) Reduction: Elevated GH levels increase lipolysis specifically in visceral adipocytes (which have higher GH receptor density than subcutaneous depots), reducing VAT while preserving lean mass — an effect demonstrated in multiple RCTs.

Lipid Profile Improvement: Reduces triglycerides and increases HDL through GH-mediated upregulation of lipoprotein lipase and hepatic lipase activity.

Cognitive Effects: Emerging research suggests GHRH signaling has direct effects on hippocampal neurogenesis and cognitive function, independent of peripheral GH/IGF-1 elevation.

Primary Sources

Falutz J, et al. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. NEJM, 357:2359–2370.
Stanley TL, et al. (2012). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 6(12):e821–e830.

NAD+

Nicotinamide Adenine Dinucleotide · Coenzyme

Longevity Cellular Energy Discovered: 1906 · Arthur Harden & William Young

Emerging Research Landscape

NAD⁺ repletion has become one of the most intensively studied interventions in aging and metabolic research, with investigations spanning multiple therapeutic areas:

Longevity & Biological Aging: A central focus of geroscience research, NAD⁺ repletion is being investigated for its ability to reverse hallmarks of aging — including mitochondrial dysfunction, cellular senescence, and epigenetic drift. Studies are examining whether restoring NAD⁺ levels to youthful ranges can modulate biological age as measured by epigenetic clocks.

Metabolic Health & Insulin Sensitivity: Clinical trials with NAD⁺ precursors (NMN, NR) and direct IV NAD⁺ are evaluating improvements in glucose tolerance, insulin sensitivity, and metabolic flexibility — with proposed mechanisms involving SIRT1-mediated enhancement of mitochondrial fatty acid oxidation.

Neuroprotection & Cognitive Function: Research is exploring NAD⁺'s role in neuronal health, with studies examining its effects on cognitive decline, Alzheimer's-related neurodegeneration, and traumatic brain injury through SIRT3-mediated mitochondrial protection and PARP-mediated DNA repair in neurons.

Cardiovascular Health: Preclinical and early clinical studies are investigating NAD⁺'s effects on endothelial function, arterial stiffness, blood pressure regulation, and cardiac mitochondrial resilience — with SIRT1 activation improving vascular nitric oxide bioavailability.

Energy, Fatigue & Physical Performance: Clinical studies are assessing whether NAD⁺ repletion improves mitochondrial ATP production, exercise endurance, and subjective energy levels — particularly in populations with age-related fatigue and mitochondrial dysfunction.

DNA Repair & Genomic Integrity: NAD⁺ is an essential substrate for PARPs (poly-ADP-ribose polymerases), and research is examining whether boosting NAD⁺ levels enhances DNA damage repair, reduces accumulation of somatic mutations, and lowers cancer risk through improved genomic surveillance.

Addiction & Substance Recovery: IV NAD⁺ infusion protocols are under investigation as adjuncts to addiction recovery programs, with preliminary reports suggesting reduced withdrawal severity and cravings in alcohol and opioid dependence — though controlled trial data remains limited.

Origin & Endogenous Production

NAD⁺ (Nicotinamide Adenine Dinucleotide) is a universal cellular coenzyme present in every living cell. It is synthesized endogenously via three main pathways: the de novo pathway from tryptophan (via the kynurenine pathway), the Preiss-Handler pathway from dietary nicotinic acid, and the salvage pathway from nicotinamide (the most predominant route in mammals). NAD⁺ levels decline significantly with age — by approximately 50% between age 40 and 60 in most tissues — a finding directly correlated with mitochondrial dysfunction, metabolic decline, and age-related disease onset.

Mechanisms of Action

Electron Transport Chain (ETC) Function: NAD⁺ is reduced to NADH during glycolysis and the TCA cycle, then oxidized back to NAD⁺ by Complex I of the mitochondrial electron transport chain — the central reaction driving ATP synthesis. Without sufficient NAD⁺, cellular energy production collapses.

Sirtuin Activation (SIRT1-7): NAD⁺ is the obligate co-substrate for all seven sirtuin deacylases. SIRT1 and SIRT3 activation deacetylates PGC-1α (stimulating mitochondrial biogenesis), FOXO3 (upregulating stress resistance genes), and p53 (modulating apoptosis). SIRT1 also activates AMPK pathways.

PARP-1 DNA Repair: Poly(ADP-ribose) polymerase-1 (PARP-1) consumes NAD⁺ to synthesize PAR chains that recruit DNA repair machinery to strand breaks. Chronic DNA damage in aging cells leads to PARP-1 hyperactivation, depleting NAD⁺ and creating a vicious cycle of energetic failure.

CD38 and Calcium Signaling: CD38 (a cyclic ADP-ribose hydrolase) is the primary NAD⁺-consuming enzyme in aging tissue. cADPR produced by CD38 mobilizes intracellular Ca²⁺ stores, regulating insulin secretion, muscle contraction, and immune cell activation.

Mitophagy & Mitochondrial Quality Control: NAD⁺/SIRT1/PGC-1α signaling is essential for mitophagy (selective elimination of dysfunctional mitochondria) and mitochondrial fission/fusion dynamics — critical determinants of cellular aging.

Primary Sources

Yoshino J, et al. (2018). NAD⁺ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab, 27(3):513–528.
Verdin E. (2015). NAD⁺ in aging, metabolism, and neurodegeneration. Science, 350(6265):1208–1213.
Rajman L, et al. (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab, 27(3):529–547.

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA-c

Longevity Mitochondrial Discovered: 2015 · Pinchas Cohen, USC

Emerging Research Landscape

MOTS-c has rapidly emerged as a molecule of significant interest in metabolic and aging research, with investigations focused on several key areas:

Exercise Mimetic Properties: One of the most compelling areas of MOTS-c research is its apparent ability to replicate some metabolic benefits of exercise — including AMPK activation, enhanced glucose uptake, and improved fatty acid oxidation — earning it the designation of a potential "exercise mimetic" in populations unable to exercise.

Insulin Resistance & Metabolic Syndrome: Preclinical studies have demonstrated that MOTS-c improves insulin sensitivity and glucose homeostasis, with proposed mechanisms involving activation of the AMPK-SIRT1-PGC-1α axis and enhanced skeletal muscle glucose uptake independent of insulin signaling.

Longevity & Biological Aging: As an endogenous mitochondrial-derived peptide (MDP), MOTS-c levels decline with age. Research is investigating whether exogenous MOTS-c supplementation can reverse age-related metabolic decline and extend healthspan — with rodent studies showing improved physical performance in aged animals.

Obesity & Fat Metabolism: Studies have examined MOTS-c's effects on preventing diet-induced obesity, reducing adiposity, and enhancing thermogenesis through improved mitochondrial function in brown and beige adipose tissue.

Bone Health & Osteoporosis: Recent preclinical research has shown MOTS-c may promote osteoblast differentiation and inhibit osteoclast activity, suggesting a role in bone density maintenance and osteoporosis prevention.

Stress Resilience & Adaptive Response: MOTS-c has been observed to translocate to the nucleus during metabolic stress, directly regulating gene expression related to the adaptive stress response (ARE and TFEB pathways) — a novel mechanism for a mitochondrial-derived peptide that is under active investigation.

Origin & Endogenous Production

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome (12S rRNA region) — a remarkable discovery by Pinchas Cohen's group in 2015 that revealed mitochondria can produce bioactive peptides with systemic hormonal functions. This class of peptides, termed mitochondrial-derived peptides (MDPs), challenges the long-held view of mitochondria as purely metabolic organelles. MOTS-c circulates in human plasma, with levels declining with age and correlating with metabolic health. Physical exercise significantly increases MOTS-c plasma concentrations, suggesting it may mediate some of exercise's systemic metabolic benefits.

Mechanisms of Action

AMPK Activation: MOTS-c activates AMP-activated protein kinase (AMPK) — the master metabolic sensor of cellular energy status — through folate and methionine cycle perturbation, increasing AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) levels that directly allosterically activate AMPK.

Insulin Sensitization: Improves skeletal muscle glucose uptake independently of insulin by promoting GLUT4 translocation to the plasma membrane via AMPK/RAC1 signaling, without engaging the insulin receptor directly.

Nuclear Translocation & Gene Regulation: Unlike most peptides, MOTS-c translocates to the nucleus in response to metabolic stress, directly binding and regulating nuclear gene expression — particularly genes in the antioxidant response element (ARE) pathway.

Folate-Methionine Cycle Regulation: MOTS-c inhibits the folate cycle enzyme MTHFD2, reducing 5-methyltetrahydrofolate production and redirecting one-carbon metabolism — a unique mechanism linking mitochondrial function to nuclear epigenetics.

Longevity Association: A specific MOTS-c variant (K14Q) is significantly enriched in Japanese centenarians, suggesting natural genetic variation in MOTS-c function influences extreme longevity.

Primary Sources

Lee C, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab, 21(3):443–454.
Reynolds JC, et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun, 12(1):470.

SS-31

Elamipretide · Szeto-Schiller Peptide 31 · MTP-131

Mitochondrial Protector Developed: 2002 · Hazel Szeto & Peter Schiller

Emerging Research Landscape

SS-31 (Elamipretide) is one of the most clinically advanced mitochondria-targeted therapeutics, with active investigations across multiple disease areas:

Heart Failure: Phase 2/3 clinical trials have evaluated SS-31 in heart failure with reduced ejection fraction (HFrEF), examining improvements in cardiac energetics, left ventricular function, and exercise capacity through restoration of mitochondrial cristae structure and cardiolipin stabilization.

Primary Mitochondrial Myopathies: The MMPOWER trials (Stealth BioTherapeutics) have studied SS-31 in patients with Barth syndrome and other inherited mitochondrial diseases, assessing improvements in exercise tolerance, fatigue, and cardiac function.

Age-Related Decline & Skeletal Muscle: Research is examining whether SS-31 reverses age-related mitochondrial dysfunction in skeletal muscle, improving oxidative capacity, reducing reactive oxygen species (ROS), and restoring exercise performance in elderly subjects.

Kidney Disease: Preclinical and early clinical studies are investigating SS-31's renoprotective effects, including reduced ischemia-reperfusion injury, improved renal mitochondrial function, and potential slowing of chronic kidney disease progression.

Ophthalmic Disease: Research is exploring SS-31's neuroprotective effects in the retina, with studies in age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma focused on protecting retinal ganglion cell mitochondria from oxidative stress.

Neurodegenerative Disease: Preclinical models have investigated SS-31 in Alzheimer's and Parkinson's disease, examining whether mitochondrial protection in neurons reduces amyloid toxicity, α-synuclein aggregation, and neuronal apoptosis.

Origin & Design

SS-31 (D-Arg-2'6'-Dmt-Lys-Phe-NH₂) is a synthetic tetrapeptide developed by Drs. Hazel Szeto and Peter Schiller, designed specifically to target the inner mitochondrial membrane (IMM). Its alternating aromatic-cationic residue pattern enables spontaneous concentration within the IMM — achieving mitochondrial levels 1,000-fold higher than cytoplasmic concentrations without requiring any active transport mechanism. SS-31 selectively binds cardiolipin, a unique phospholipid exclusive to the IMM that is essential for the structural integrity and electron transport function of the respiratory chain.

Mechanisms of Action

Cardiolipin Binding & Stabilization: Cardiolipin undergoes peroxidation under oxidative stress, disrupting the cristae architecture and ETC Complex assembly. SS-31's interaction with cardiolipin prevents peroxidation, stabilizes the inner membrane curvature, and maintains cristae ultrastructure essential for ATP synthase oligomerization.

Cytochrome c Sequestration: Cardiolipin-bound cytochrome c acts as a peroxidase (generating ROS). SS-31 reduces cytochrome c's peroxidase activity by ~90% by altering its interaction geometry with cardiolipin, dramatically reducing mitochondrial ROS production.

ETC Efficiency Restoration: Restores electron flow through Complexes I, III, and IV by stabilizing their super-complex assembly (respirasomes), increasing ATP production efficiency and reducing proton leak.

Mitochondrial Morphology: Reverses age-associated mitochondrial fragmentation by supporting the fusion machinery (Mfn1/2, OPA1), which requires proper inner membrane potential and cardiolipin integrity.

Primary Sources

Szeto HH. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol, 171(8):2029–50.
Birk AV, et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol, 24(8):1250–61.

Thymosin Alpha-1

Tα1 · Zadaxin · Thymalfasin

Immune Modulator Isolated: 1972 · Allan Goldstein, George Washington U.

Emerging Research Landscape

Thymosin Alpha-1, approved in over 35 countries as Zadaxin, has one of the most extensive clinical evidence bases of any immunomodulatory peptide:

Immune System Enhancement & Immunodeficiency: Research has extensively studied Tα1's ability to enhance T-cell maturation, increase NK cell activity, and promote dendritic cell differentiation — with clinical applications in primary immunodeficiency, post-transplant immune reconstitution, and age-related immune decline (immunosenescence).

Chronic Viral Hepatitis: Tα1 is approved in multiple countries as adjunct therapy for hepatitis B and C, with clinical trials demonstrating improved viral clearance rates, enhanced interferon responsiveness, and reduced progression to cirrhosis.

Cancer Immunotherapy Adjunct: Studies have investigated Tα1 as an adjuvant to chemotherapy and immunotherapy, examining whether enhanced T-cell and dendritic cell function improves tumor-specific immune responses, reduces treatment-related immunosuppression, and improves survival in hepatocellular carcinoma, melanoma, and NSCLC.

Sepsis & Critical Illness: Research has evaluated Tα1 in severe sepsis and septic shock, with Chinese critical care trials showing reduced mortality and improved immune function markers when added to standard of care.

Vaccine Enhancement: Studies have examined Tα1 as a vaccine adjuvant to improve antibody and cellular immune responses, particularly in immunocompromised and elderly populations with poor vaccine responsiveness.

Respiratory Infections: During the COVID-19 pandemic, Tα1 was studied in Chinese hospital settings for its potential to restore lymphocyte counts and improve outcomes in patients with severe lymphopenia and immune dysregulation.

Origin & Endogenous Production

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced and secreted by thymic epithelial cells. It represents the N-terminal fragment of a larger precursor protein, Prothymosin Alpha. The thymus gland — the primary organ of T-cell maturation — secretes Tα1 as a key hormonal signal coordinating adaptive immunity. Thymic output and Tα1 levels decline sharply after puberty as the thymus involutes, contributing to the age-related deterioration of T-cell-mediated immune function. Tα1 is FDA-approved in over 35 countries (as Zadaxin) for hepatitis B, hepatitis C, and as an adjuvant in cancer immunotherapy.

Mechanisms of Action

T-Cell Maturation & Differentiation: Promotes thymocyte differentiation into mature CD4⁺ and CD8⁺ T lymphocytes by upregulating T-cell receptor (TCR) expression and signaling competence in immature thymocytes.

Dendritic Cell Activation: Stimulates TLR9 signaling in plasmacytoid dendritic cells (pDCs), triggering IFN-α production — a critical innate antiviral response and bridge to adaptive immunity.

Th1/Th2 Balance: Promotes a Th1-dominant immune response (cell-mediated immunity) by inducing IL-2, IFN-γ, and IL-12 production from T-helper cells, while moderating excessive Th2 (allergic/humoral) responses.

NK Cell Enhancement: Upregulates natural killer (NK) cell cytotoxicity against virus-infected and tumor cells by increasing perforin and granzyme expression.

Autophagy Induction: Recent studies demonstrate Tα1 triggers autophagy in macrophages via Beclin-1 upregulation, enhancing pathogen clearance and reducing chronic inflammation.

Primary Sources

Garaci E, et al. (2012). Thymosin alpha 1: From bench to bedside. Ann N Y Acad Sci, 1269:96–103.
Romani L, et al. (2004). Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood, 108(7):2265–74.

Pinealon

EDR · Glu-Asp-Arg tripeptide

Neuropeptide Geroprotective Developed: 1990s · Khavinson Institute, St. Petersburg

Emerging Research Landscape

Pinealon is one of several short "bioregulatory" peptides developed by the Khavinson laboratory, with research focused on its neuroactive properties:

Neuroprotection & Cognitive Function: Preclinical research has investigated Pinealon's ability to protect neurons against oxidative stress, hypoxia, and amyloid-β toxicity, with proposed applications in age-related cognitive decline and neurodegenerative disease prevention.

Sleep & Circadian Regulation: Studies have examined Pinealon's effects on pinealocyte function and melatonin synthesis, with data suggesting it may help normalize disrupted circadian rhythms — particularly relevant for age-related sleep fragmentation and jet lag.

Antioxidant & Anti-Aging Properties: Research has explored Pinealon's capacity to reduce oxidative stress markers in brain tissue, with Khavinson's group reporting improved survival and reduced spontaneous tumor incidence in long-term animal studies.

Gene Expression Modulation: As a bioregulatory peptide, Pinealon is being studied for its ability to interact directly with DNA and modulate gene expression patterns in neural tissue — a mechanism shared with other Khavinson peptides (Epitalon, Vilon, Thymalin).

Origin & Endogenous Context

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) derived from the research of Prof. Khavinson's group, representing a bioregulatory peptide with affinity for brain and pineal gland tissue. It belongs to the class of short peptide bioregulators (cytomedines) developed from organ-specific polypeptide extracts, where tissue-specific short peptides were identified as carrying tissue-targeting biological information. Pinealon exhibits particular affinity for neuronal cells and has demonstrated neuroprotective and neurorestorative properties in multiple in vitro and in vivo models.

Mechanisms of Action

Chromatin Remodeling: Pinealon and similar short peptides interact directly with DNA through intercalation and groove binding, altering chromatin compaction and modulating gene expression in a tissue-specific manner — a proposed mechanism for the "bioregulator" class of peptides.

Neuroprotection Under Hypoxia: Demonstrated to protect neurons from ischemic and hypoxic injury by reducing caspase-3 activation, maintaining mitochondrial membrane potential, and reducing excitotoxic calcium influx.

Antioxidant Gene Upregulation: Increases expression of SOD1, catalase, and thioredoxin in neural tissue, enhancing the brain's endogenous antioxidant defenses.

Serotonin System Modulation: Evidence suggests interaction with serotonergic pathways in the pineal region, potentially contributing to circadian entrainment effects observed alongside Epitalon.

Primary Sources

Khavinson VKh & Malinin VV. (2005). Gerontological Aspects of Genome Peptide Regulation. Karger (Basel).
Khavinson V, et al. (2011). Peptide regulation of aging. Front Biosci (Schol Ed), 3:194–206.

Selank

TP-7 · Tuftsin Analogue · Heptapeptide

Anxiolytic Neuropeptide Immune-Neuro Developed: 1990s–2000s · IBMC, Moscow

Emerging Research Landscape

Selank, approved in Russia as an anxiolytic, has generated research interest across neurological and immunological domains:

Anxiety & Mood Disorders: Clinical research has evaluated Selank's anxiolytic properties, with studies reporting reductions in generalized anxiety comparable to benzodiazepines but without sedation, cognitive impairment, or dependence — with proposed mechanisms involving modulation of GABA-A receptor expression and serotonergic signaling.

Cognitive Enhancement & Nootropic Effects: Research has investigated Selank's effects on memory formation, attention, and learning — with data suggesting enhancement of BDNF (brain-derived neurotrophic factor) expression and hippocampal neuroplasticity.

Immune Modulation: As a tuftsin analogue, Selank retains immunomodulatory properties. Studies have examined its effects on inflammatory cytokine balance, IL-6 expression, and immune regulation — with dual anxiolytic-immunomodulatory action being a unique feature among anti-anxiety agents.

Neuroprotection: Preclinical research is exploring Selank's ability to protect neurons under conditions of ischemia, oxidative stress, and excitotoxicity, with proposed mechanisms involving stabilization of enkephalin degradation and enhancement of endogenous opioid signaling.

Gene Expression & Neurogenomics: Microarray studies have revealed that Selank modulates expression of over 50 genes related to neural signaling, inflammation, and apoptosis — an area of active research for understanding its broad neurological effects.

Origin & Endogenous Context

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analogue of Tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of IgG immunoglobulin through enzymatic cleavage. Tuftsin is produced in the spleen and is a key endogenous immunomodulator. Selank extends the Tuftsin sequence with an additional Pro-Gly-Pro fragment from the ECM protein proline-rich peptides, dramatically increasing metabolic stability. It has undergone clinical trials in Russia and received approval there as an anxiolytic drug.

Mechanisms of Action

GABAergic Modulation: Selank increases the expression and membrane density of GABA-A receptor subunits (particularly α1, β2, γ2), enhancing GABAergic inhibitory tone — producing anxiolytic effects without the receptor downregulation or dependence associated with benzodiazepines.

BDNF Upregulation: Significantly increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus and frontal cortex, supporting neuroplasticity, memory consolidation, and resilience to stress-induced neuronal damage.

Enkephalin Stabilization: Inhibits enkephalinases — enzymes that rapidly degrade endogenous opioid peptides — thereby prolonging the action of met-enkephalin and leu-enkephalin in the brain's stress response circuits.

Cytokine Balance: Normalizes IL-6, TNF-α, and IFN-γ dysregulation in stress models, reducing neuroinflammation while preserving immune competence — an important distinction from immunosuppressive anxiolytics.

Primary Sources

Semenova TP, et al. (2010). Selank and short tuftsin peptides cause similar changes in the expression of genes involved in the GABAergic system of rats. Doklady Biol Sci, 430:8–11.
Narkevich VB, et al. (2008). Effects of the heptapeptide selank on the content of monoamines and their metabolites. Eksp Klin Farmakol, 71(2):8–11.

Semax

ACTH(4-7)PGP · Nootropic Heptapeptide

Cognitive Neuropeptide Developed: 1982–2011 · Institute of Molecular Genetics, Moscow

Emerging Research Landscape

Semax, approved in Russia as both a nootropic and neuroprotective agent, has been studied across several neurological research domains:

Stroke & Ischemic Brain Injury: Clinical studies in Russia have investigated Semax as an acute treatment for ischemic stroke, with data suggesting reduced infarct volume, improved neurological recovery, and enhanced cerebral blood flow when administered alongside standard thrombolytic therapy.

Cognitive Enhancement & Memory: Research has evaluated Semax's nootropic effects, with studies reporting improvements in attention, working memory, and cognitive flexibility — proposed mechanisms involve increased BDNF and NGF (nerve growth factor) expression in the hippocampus and prefrontal cortex.

ADHD & Attention Disorders: Clinical investigations have explored Semax as a treatment for attention deficit disorders, with preliminary data suggesting improved sustained attention and reduced impulsivity without the sympathomimetic effects of stimulant medications.

Optic Nerve & Visual Function: Studies have examined Semax (applied intranasally) for optic nerve atrophy and glaucoma, with Russian clinical data reporting improved visual acuity and visual field parameters in patients with optic neuropathy.

Neurotrophic Factor Modulation: Research into Semax's effects on BDNF, NGF, and other neurotrophins represents an active area of investigation, with implications for neurodegenerative disease, depression, and age-related cognitive decline.

Origin & Endogenous Context

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on the 4th to 7th amino acid sequence of Adrenocorticotropic Hormone (ACTH), the pituitary peptide that regulates cortisol synthesis. The ACTH(4-7) core (Met-Glu-His-Phe) is the primary neuroactive fragment of ACTH, and Semax extends this with a C-terminal PGP sequence to prevent rapid degradation. Unlike full ACTH, Semax has no steroidogenic activity — it lacks the receptor domains required to stimulate cortisol production — but retains the neurotrophin-stimulating and cognitive properties of the ACTH molecule.

Mechanisms of Action

BDNF & NGF Upregulation: Semax produces rapid, robust increases in hippocampal BDNF and NGF (Nerve Growth Factor) mRNA and protein expression, enhancing synaptic plasticity, long-term potentiation (LTP), and neuronal survival.

Dopaminergic & Serotonergic Enhancement: Increases dopamine turnover in the prefrontal cortex and striatum, and augments 5-HT (serotonin) signaling in limbic regions — improving motivation, mood, and cognitive processing speed.

Melanocortin Receptor Interaction: Engages melanocortin receptors (MC4R in the brain) via the ACTH core sequence, activating cAMP/PKA pathways that regulate synaptic protein synthesis and neural network function.

Neuroprotection in Ischemia: Reduces infarct volume and neurological deficit in stroke models by upregulating heat shock proteins (HSP70), reducing glutamate excitotoxicity, and promoting VEGF-mediated angiogenesis in peri-infarct cortex.

Primary Sources

Shadrina MI, et al. (2001). Semax influences the expression of brain neurotrophic factors. Molekuliarnaia Biologiia, 35(3):390–394.
Gusev EI, et al. (1997). The neuroprotective effects of semax in clinical practice. Zh Nevrol Psikhiatr, 97(10):26–34.

IGF-1 LR3

Insulin-like Growth Factor-1 Long R3 · Long-acting IGF-1 analogue

IGF-1 Axis Anabolic / Metabolic IGF-1 characterized: 1957 · Salmon & Daughaday

Emerging Research Landscape

IGF-1 LR3, with its extended half-life and enhanced bioavailability, has driven research interest across growth, recovery, and metabolic domains:

Muscle Hypertrophy & Regeneration: Research has investigated IGF-1's potent effects on skeletal muscle satellite cell activation, myoblast proliferation, and protein synthesis — with studies examining its role in accelerating muscle recovery, promoting hypertrophy, and combating sarcopenia in aging and disuse atrophy.

Metabolic Health & Insulin Sensitivity: Studies have examined IGF-1's glucose-lowering effects through activation of the IGF-1R (which shares downstream signaling with the insulin receptor), with investigations into improved insulin sensitivity and potential applications in insulin-resistant states.

Connective Tissue & Cartilage: Research is evaluating IGF-1's anabolic effects on chondrocytes, fibroblasts, and collagen synthesis — with implications for joint health, tendon repair, and cartilage regeneration in osteoarthritis.

Neuroprotection & Cognitive Function: IGF-1 crosses the blood-brain barrier and activates neuronal IGF-1R — studies are investigating its effects on hippocampal neurogenesis, synaptic plasticity, and neuroprotection against age-related cognitive decline.

Bone Health: As a critical mediator of GH's anabolic effects on bone, IGF-1 research includes its role in osteoblast differentiation, bone mineral density, and fracture healing — with IGF-1 LR3's enhanced potency being of particular interest.

Wound Healing: Research has examined topical and systemic IGF-1 for accelerated wound closure, enhanced granulation tissue formation, and improved healing in diabetic ulcers and chronic wounds.

Origin & Endogenous Context

Endogenous IGF-1 (Insulin-like Growth Factor-1) is a 70-amino-acid single-chain polypeptide primarily synthesized in the liver in response to growth hormone (GH) receptor activation via JAK2/STAT5b signaling. It is also produced locally in virtually every tissue (autocrine/paracrine IGF-1) where it mediates GH's tissue-building effects. Plasma IGF-1 is bound to IGF binding proteins (IGFBPs 1-6), which regulate its bioavailability — only ~1% of circulating IGF-1 is free and active. IGF-1 LR3 is an 83-amino-acid synthetic analogue containing an N-terminal 13-amino-acid extension and a glutamate → arginine substitution at position 3, which drastically reduces IGFBP binding affinity, extending its half-life from ~12 hours to ~20–30 hours and greatly increasing systemic bioavailability.

Mechanisms of Action

IGF-1 Receptor (IGF1R) Activation: Binds the IGF-1 receptor — a receptor tyrosine kinase (RTK) — triggering autophosphorylation of the β-subunit and activation of IRS-1/PI3K/AKT/mTOR and RAS/MAPK/ERK pathways, which drive protein synthesis, cell proliferation, and survival.

mTORC1 Activation & Protein Synthesis: AKT-mediated phosphorylation of TSC1/2 releases mTORC1 from inhibition, activating S6K1 and 4E-BP1 — the master regulators of ribosomal protein translation and overall cellular anabolic rate.

Satellite Cell Activation: IGF-1 is the primary activator of muscle satellite cells (resident stem cells), driving their proliferation (myoblast expansion) and differentiation (myotube formation) essential for skeletal muscle hypertrophy and repair.

Anti-Apoptotic Signaling: AKT phosphorylates and inactivates pro-apoptotic proteins BAD and caspase-9, and promotes FOXO3 nuclear exclusion, reducing programmed cell death in stressed tissues.

Glucose Uptake: Activates PI3K/AKT-mediated GLUT4 translocation in muscle and adipose tissue via a pathway partially overlapping with insulin receptor signaling, lowering blood glucose independently of insulin.

Primary Sources

Francis GL. (2010). Insulin-like growth factor I and the IGF receptor: structural bases for bioactivity. Endocr Dev, 19:1–12.
Laviola L, et al. (2007). The IGF-I signaling pathway. Curr Pharm Des, 13(7):663–9.
LeRoith D & Roberts CT Jr. (2003). The insulin-like growth factor system and cancer. Cancer Lett, 195(2):127–137.

Kisspeptin

KISS1 gene product · Metastin · KP-10/KP-54

Reproductive Axis Neuroendocrine Identified: 2001 · Lee et al. / Ohtaki et al.

Emerging Research Landscape

Kisspeptin has emerged as a critical regulator of reproductive biology, with expanding research into hormonal health and fertility:

Fertility & Reproductive Endocrinology: Clinical trials have investigated Kisspeptin as a novel trigger for oocyte maturation in IVF protocols, offering a more physiologic alternative to hCG with potentially reduced risk of ovarian hyperstimulation syndrome (OHSS).

Hypothalamic Amenorrhea: Research has examined Kisspeptin's ability to restore pulsatile GnRH secretion in women with functional hypothalamic amenorrhea — a condition marked by suppressed kisspeptin signaling due to stress, low body weight, or excessive exercise.

Male Hypogonadism & Testosterone: Studies are evaluating Kisspeptin as a potential stimulator of the HPG axis in men with functional hypogonadism, offering a way to increase endogenous testosterone production without exogenous testosterone's suppressive effects on spermatogenesis.

Sexual Desire & Psychosexual Function: Brain fMRI studies by Dhillo et al. have demonstrated that Kisspeptin activates limbic brain regions associated with sexual arousal and attraction, with clinical trials investigating its potential in hypoactive sexual desire disorder.

Puberty Timing & Disorders: Research is exploring Kisspeptin's role in the timing of puberty onset, with implications for understanding and treating precocious puberty and delayed puberty.

Metabolic-Reproductive Crosstalk: Studies are investigating how Kisspeptin neurons integrate metabolic signals (leptin, insulin, ghrelin) with reproductive function — relevant to understanding infertility associated with obesity, diabetes, and metabolic syndrome.

Origin & Endogenous Production

Kisspeptin is a family of neuropeptides derived from the KISS1 gene, produced primarily by hypothalamic KNDy neurons (neurons co-expressing Kisspeptin, Neurokinin B, and Dynorphin) in the arcuate nucleus and anteroventral periventricular nucleus. The KISS1 precursor protein is cleaved into bioactive fragments including KP-54, KP-14, KP-13, and KP-10 — all of which bind the same receptor. Kisspeptin was originally discovered as a metastasis suppressor gene product ("metastin") before its central role in controlling the reproductive axis was revealed. It serves as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis.

Mechanisms of Action

GPR54 (KISS1R) Activation: Kisspeptin binds its receptor GPR54 (a Gαq/11-coupled GPCR) on hypothalamic GnRH neurons, triggering PLCβ → IP3/DAG → PKC cascade and Ca²⁺ mobilization, stimulating GnRH pulse release.

GnRH Pulsatility Control: KNDy neuron networks act as the hypothalamic pulse generator, with Kisspeptin initiating GnRH pulses while Neurokinin B amplifies them and Dynorphin terminates each pulse — creating the precise episodic GnRH secretion necessary for normal LH/FSH release.

LH Surge Induction: Kisspeptin neurons in the AVPV nucleus (in females) drive the preovulatory LH surge in response to rising estradiol levels, directly triggering ovulation.

Steroid Feedback Integration: Kisspeptin neurons serve as the primary integration site for sex steroid feedback (estrogen, testosterone, progesterone) onto the GnRH axis, explaining the regulation of puberty onset, fertility, and reproductive aging.

Primary Sources

Oakley AE, et al. (2009). Kisspeptin signaling in the brain. Endocr Rev, 30(6):713–43.
Seminara SB, et al. (2003). The GPR54 gene as a regulator of puberty. NEJM, 349(17):1614–27.

Melanotan II

MT-II · cyclo[Nle4,D-Phe7]-α-MSH analogue

Melanocortin Agonist Neuroendocrine Synthesized: 1991 · University of Arizona (Hruby/Hadley)

Emerging Research Landscape

Melanotan II's multi-receptor activity has generated research interest across several distinct physiological domains:

Photoprotection & Skin Cancer Prevention: Research has investigated whether MT-II-induced melanogenesis provides functional UV protection, with studies examining whether enhanced eumelanin production reduces DNA damage from ultraviolet radiation — of particular interest for fair-skinned populations at high risk for melanoma.

Erythropoietic Protoporphyria (EPP): The related compound afamelanotide (a linear α-MSH analogue derived from MT-II research) was FDA-approved for EPP, validating the melanocortin pathway as a therapeutic target for photosensitivity disorders.

Sexual Dysfunction: MT-II's activation of MC4R in hypothalamic and spinal cord circuits has been studied for its effects on libido and erectile function, directly leading to the development of PT-141 (bremelanotide) as an FDA-approved sexual dysfunction treatment.

Appetite Regulation & Obesity: MC4R is a key node in central appetite regulation, and MT-II's anorectic effects have been studied in the context of obesity research — though its non-selective receptor profile limits clinical development for this indication.

Compulsive Behavior & Addiction: Preclinical research has explored melanocortin signaling in reward circuits, with studies examining whether MC4R activation modulates alcohol consumption, drug-seeking behavior, and compulsive eating.

Origin & Endogenous Context

Melanotan II is a synthetic cyclic 7-amino-acid analogue of α-Melanocyte Stimulating Hormone (α-MSH), itself a 13-amino-acid peptide cleaved from the precursor protein Pro-opiomelanocortin (POMC) in the pituitary intermediate lobe and hypothalamic POMC neurons. The melanocortin system — comprising α-MSH, β-MSH, γ-MSH, and ACTH (all POMC-derived) and their five receptors (MC1R–MC5R) — serves as a master regulator of pigmentation, energy balance, inflammation, sexual function, and immune modulation. Melanotan II was designed as a metabolically stable, more potent α-MSH analogue for research into melanocortin physiology.

Mechanisms of Action

MC1R Activation (Melanogenesis): Binds MC1R on melanocytes, activating adenylyl cyclase → cAMP → PKA → MITF (Microphthalmia-associated transcription factor), upregulating tyrosinase and eumelanin synthesis — the photoprotective brown/black pigment.

MC3R/MC4R Appetite & Energy: Hypothalamic MC4R activation reduces food intake via POMC/CART neuronal signaling (opposing the orexigenic NPY/AgRP pathway), increases energy expenditure through sympathetic nervous system activation, and regulates fat oxidation.

MC4R & Sexual Function: Spinal MC4R activation through oxytocinergic pathways promotes central sexual arousal and genital vasodilatation — the mechanism underlying PT-141's (bremelanotide) development from Melanotan II.

MC1R Anti-inflammatory: α-MSH/MC1R signaling in macrophages and keratinocytes inhibits NF-κB, reduces TNF-α, IL-1β, and iNOS expression, contributing to potent anti-inflammatory effects in skin and other tissues.

Primary Sources

Hadley ME & Dorr RT. (2006). Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization. Peptides, 27(4):921–930.
Catania A. (2007). The melanocortin system in leukocyte biology. J Leukoc Biol, 81(2):383–92.

PT-141

Bremelanotide · Vyleesi (FDA-approved) · Cyclic peptide

Melanocortin / Sexual Function FDA Approved: 2019 · AMAG Pharmaceuticals

Emerging Research Landscape

As the only FDA-approved melanocortin-based sexual health therapeutic, PT-141 has an established clinical profile with expanding research frontiers:

Female Hypoactive Sexual Desire Disorder (HSDD): FDA-approved as Vyleesi for premenopausal women with HSDD, clinical trials (RECONNECT program) demonstrated significant improvements in sexual desire and distress scores, establishing melanocortin-based therapy as a novel central mechanism for female sexual health.

Male Erectile Dysfunction: Phase 2/3 clinical trials investigated PT-141 for erectile dysfunction, with studies showing efficacy in patients who had failed PDE5 inhibitors (sildenafil, tadalafil) — suggesting a complementary central mechanism of action distinct from peripheral vasodilatory approaches.

Central Arousal Pathways: Research is investigating PT-141's unique mechanism of acting on hypothalamic MC4R to activate central arousal pathways rather than peripheral vascular targets — providing a model for understanding the neuroscience of sexual desire and developing novel therapeutic approaches.

Medication-Induced Sexual Dysfunction: Studies are exploring PT-141's potential utility in patients experiencing sexual dysfunction secondary to SSRI antidepressants, hormonal therapies, or other medications that impair central arousal signaling.

Hemorrhagic Shock: Interestingly, early research also investigated melanocortin agonism for its hemodynamic effects, with preclinical data showing PT-141 and related compounds improved survival in hemorrhagic shock models through MC1R-mediated anti-inflammatory pathways.

Origin & Endogenous Context

PT-141 (Bremelanotide) emerged directly from research on Melanotan II — when clinical volunteers studying its tanning effects unexpectedly reported spontaneous sexual arousal, investigators recognized the profound MC4R-mediated sexual function pathway. PT-141 is a cyclic heptapeptide metabolite of Melanotan II, formed by removal of the C-terminal amide group, and became the focus of sexual dysfunction research. It was FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first centrally-acting treatment for female sexual dysfunction, representing a fundamentally different mechanism from PDE5 inhibitors which act peripherally.

Mechanisms of Action

Central MC4R Activation: PT-141 activates MC4R in the medial preoptic area (MPOA) of the hypothalamus — a critical node for integrating hormonal and neurochemical signals governing sexual motivation. This central mechanism is fundamentally distinct from peripheral vasogenic drugs.

Oxytocin Pathway Engagement: MC4R activation in the hypothalamus stimulates oxytocinergic neurons in the paraventricular nucleus (PVN), increasing oxytocin release — the neurochemical mediator of bonding, trust, and sexual arousal — which then acts on spinal nuclei controlling genital vasocongestive response.

Dopaminergic Motivation Enhancement: Activates the mesolimbic dopaminergic reward system via MC4R-expressing neurons projecting to the nucleus accumbens, increasing motivational salience for sexual stimuli independent of hormonal status.

Nitric Oxide Pathway (Peripheral): Downstream oxytocinergic signaling in penile/clitoral tissue activates nNOS and eNOS, producing NO-mediated smooth muscle relaxation and genital engorgement — providing both central desire and peripheral response.

Primary Sources

Clayton AH, et al. (2016). Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women. Obstet Gynecol, 128(3):536–547.
Pfaus JG, et al. (2004). The role of melanocortins in sexual function. Eur Urol Suppl, 3(4):4–9.
King SH, et al. (2007). Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem, 7(11):1098–1106.

No peptides found matching your search.

Precision Tools for Peptide Research

Reconstitution Calculator

Interaction Checker

Half-Life Visualizer

Protocol Reference

Quarterly Reviews

Peptide Research Search

Peptide Encyclopedia

Dosage & Reconstitution Calculator

Peptide Encyclopedia

Quarterly Literature Reviews

GLP-1 Trials Push Into Neurology & The First Head-to-Head Showdown

Search Peptide Research

BPC-157 & Tendon Repair — January 2025

BPC-157 Mechanisms of Action — December 2024

BPC-157 Neurological Applications — November 2024

Precision Tools for Peptide Research

Reconstitution Calculator

Interaction Checker

Half-Life Visualizer

Protocol Reference

Quarterly Reviews

Peptide Research Search

Peptide Encyclopedia

Dosage & Reconstitution Calculator

Peptide Encyclopedia

Quarterly Literature Reviews

GLP-1 Trials Push Into Neurology & The First Head-to-Head Showdown

Search Peptide Research

BPC-157 & Tendon Repair — January 2025

BPC-157 Mechanisms of Action — December 2024

BPC-157 Neurological Applications — November 2024

Unlock Full Research Access